

Jarosław Sączewski*, Anna Kędzia and Aleksandra Jalińska

New derivatives of 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one: synthesis, tautomerism, electronic structure and antibacterial activity

Abstract: The electronic structure and prototropic tautomerism of 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) were studied theoretically with use of the B3LYP/6-31G* and ω B97X-D/6-31G* density functional methods and SM8 (H₂O, DMF) solvation models. Compound **1**, which is a weak acid with a pK_a of 6.9, undergoes regioselective alkylation and sulfonylation under basic reaction conditions to give a series of *N*1-substituted products **2a–i**. Later compounds were evaluated *in vitro* for antibacterial activity with the use of 68 strains of aerobic and anaerobic bacteria, including 12 reference strains.

Keywords: acidity; antibacterial activity; DFT quantum chemical calculations; isoxazolo[3,4-*b*]pyridin-3(1*H*)-one; *N*-alkylation; mesomerism.

DOI 10.1515/hc-2014-0107

Received June 19, 2014; accepted June 22, 2014; previously published online July 17, 2014

Introduction

It is well known that substituted 2,1-isoxazol-3-ones possess interesting pharmacological properties such as antibacterial [1–4], antitubercular [1], fungicidal [5, 6], antileukemic [4], antioxidant [3] and antiandrogenic [7] activities. They also act as inhibitors of tumor necrosis factor- α (TNF- α) [8] and inhibitors of p38 MAP kinases [9].

Recently, we have used 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) as a substrate for the fluorogenic tandem Mannich-electrophilic amination reaction with formaldehyde and secondary amines, which give rise to

the formation of a new class of photostable fluorescent dyes with a [1, 2, 4]triazolo[3,4-*b*]pyridin-2-ium core structure [10–12].

In the present work, we describe the *N*-alkylation and *N*-sulfonylation reactions of **1** and antibacterial properties of the newly obtained isoxazolo[3,4-*b*]pyridin-3(1*H*)-one derivatives **2a–i**. To understand the observed regioselectivity of the above reactions, theoretical studies on tautomerism of **1** and electronic structure of the most stable tautomers 1*H*-oxo (**1-A**), 7*H*-oxo (**1-B**) have been carried out using the B3LYP/6-31G* and ω B97X-D/6-31G* density functional methods.

Results and discussion

Synthesis


4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) was synthesized according to a previously described procedure [13] with minor modification. As shown in Scheme 1, the condensation of *N*-hydroxy-3-(hydroxyamino)-3-iminopropanamide [14] with acetylacetone in the presence of piperidine resulted in a yellow-colored solution of salt **A** from which, upon neutralization with aqueous 10% HCl, the solid product **1** precipitated in good yield.

Previously, the exploration of chemical reactivity of compound **1** has revealed that acetylation and benzylation take place exclusively at the *N*1 nitrogen atom [13, 15]. We have now found evidence that alkylation and sulfonylation of **1** also proceed regioselectively at the *N*1 nitrogen atom (Scheme 2). Due to poor solubility of **1** in aprotic organic solvents such as benzene or chloroform, the alkylation reaction was carried out in a mixture of chloroform and *N,N*-dimethylformamide (DMF) in the presence of triethylamine (Scheme 2). Pure products **2a–g** were isolated by means of a preparative, centrifugally accelerated, radial, thin-layer chromatography (chromatotron) in 62–84% yield. By contrast, the methylsulfonyl derivative **2h** was obtained by reacting **1** with methanesulfonyl chloride in aqueous 5% NaOH

*Corresponding author: Jarosław Sączewski, Department of Organic Chemistry, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland, e-mail: js@gumed.edu.pl

Anna Kędzia: Department of Oral Microbiology, Medical University of Gdańsk, ul. Do Studzienki 38, 80-227 Gdańsk, Poland


Aleksandra Jalińska: Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416, Gdańsk, Poland



Scheme 1 Synthesis of 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**).

solution, followed by chromatographic purification on silica gel. The acetyl derivative **2i**, which was required for biological tests, was synthesized according to the literature procedure [15].

The regioselectivity of the above reactions, that is, formation of *N*1-substituted products, has been confirmed by



Scheme 2 Alkylation, acetylation and sulfonylation of **1**.

NMR measurements (lack of NOE between substituents at the *N*1 position and protons of 6-CH₃ group) and the previously reported single crystal X-ray diffraction analysis of compound **2i** [15].

pK_a, prototropic tautomerism and electronic structure of **1**

Potentiometric titration of the NH acid **1** with use of 0.1 N NaOH has shown that its aqueous pK_a value is 6.9 (Figure 1), which indicates that it is more acidic than benzotriazole (pK_a = 8.38) [16], 1,2,3-triazole (pK_a = 9.26), 1,2,4-triazole (pK_a = 10.04) and significantly less acidic than tetrazole (pK_a = 4.89) [17]. Starting point of pH = 3 adjusted with 0.1 N HCl.

To obtain insight into the chemical properties of the isoxazolo[3,4-*b*]pyridin-3-one ring system, we have theoretically analyzed all three possible tautomeric forms: 1*H*-oxo (**1-A**), 7*H*-oxo (**1-B**) and hydroxy (**1-C**) (Figure 2) with use of the B3LYP/6-31G* and ωB97X-D/6-31G* density functional methods and SM8 (H₂O, DMF) solvation models [18–21]. It appears that in the gas phase the most stable is the 1*H*-oxo tautomer **1-A**, which also has the smallest dipole moment. However, the DFT calculations indicate that in a solution of high relative permittivity (H₂O and DMF) the 7*H*-oxo tautomer **1-B** is more stable than the 1*H*-oxo form **1-A** by approximately 1.5 kcal mol^{−1}. Therefore, according to the Boltzmann distribution, in solvents such as H₂O or DMF an estimated ratio of **1-A** to **1-B** may be 1:20, which is in agreement




Figure 1 Potentiometric titration of compound **1** in water with use of 0.1 N NaOH.




Figure 2 Relative enthalpies of formation ΔH° (kcal mol⁻¹, 298.15 K) and dipole moments μ (debye) of tautomeric forms **1-A**, **1-B** and **1-C** calculated using B3LYP and ω B97X-D density functional methods and SM8 (H₂O, DMF) solvation models [18, 19].




Figure 3 Alkylation sites at heterocyclic amidines **D** and guanidines **E**.

with the following principles: (i) in polar solvents the dynamic equilibrium favors the more polar structure [22–25] and (ii) the most polar tautomer of a given compound is generally the one to be found in the solid state [23, 26]. According to our calculations, the hydroxy tautomer **1-C** is generally the least stable which, in turn, is in accordance with the previous examinations of tautomeric equilibrium for simple 5-hydroxyisoxazoles [27–29].

As shown in Figure 3, the alkylation reactions of both the heterocyclic amidine derivatives **D**, described as 1,3-dinucleophiles [30] or ‘protomeric ambident nucleophiles’ [31] and heterocyclic guanidines **E**, such as 2-aryliminoimidazolidines [32] or *O*-substituted imidazolidin-2-one oximes [33, 34], usually occur at a pyridine-type sp² hybridized endo- or exo-cyclic nitrogen atom.

To identify reactive sites at the amidine moiety of compound **1**, we have performed quantum-chemical calculations and molecular modeling, through which the electronic properties of the annular tautomers **1-A** and **1-B** as well as the anion **F** have been revealed. As shown in Figure 4, in all cases (**1-A**, **1-B** and **F**) the magnitude of the calculated charges are higher at the N7 nitrogen atoms. By contrast, the HOMO orbital density [$\sqrt{e/\text{au}^3}$] mapped on isodensity surface (0.002 e/au³), corresponding to the molecular size and shape, is




Figure 4 The HOMO absolute values [$\sqrt{e/\text{au}^3}$] mapped on the isodensity surface (0.002 e/au³) and N1/N7 atomic charges for the tautomers **1-A** (left) and **1-B** (middle) as well as the anion **F** (right) calculated with the ω B97X-D/6-31G* method.

Table 1 *In vitro* antibacterial activity of compounds **1**, **2a**, **b**, **2d–i** against anaerobic bacterial strains.

Bacteria (number of strains)	Minimum inhibitory concentration (MIC, $\mu\text{g mL}^{-1}$)				
	Metronidazole	1	2a	2b	2d
Gram-positive cocci:					
<i>Fingoldia magna</i> (3)	≤ 0.4	200(2), 50	200, 100, 50	100, 12.5, <6.2	≥ 200
<i>Parvimonas micra</i> (2)	≤ 0.4	100	100	50, <6.2	200, 100
<i>Peptostreptococcus anaerobius</i> (1)	1.6	25	50	100	100
Gram-positive rods:					
<i>Bifidobacterium breve</i> (2)	50, 25	100	≥ 200	≥ 200	100, 50
<i>Propionibacterium acnes</i> (1)	>100	50	50	100	≥ 200
<i>Propionibacterium granulosum</i> (2)	≥ 100	100	200, 100	≥ 200	≥ 200
Gram-negative rods:					
<i>Bacteroides fragilis</i> (1)	<0.4	100	>200	>200	>200
<i>Bacteroides uniformis</i> (1)	<0.4	50	>200	>200	>200
<i>Bacteroides ureolyticus</i> (1)	1.6	50	200	>200	>200
<i>Bacteroides vulgatus</i> (1)	<0.4	>200	100	100	100
<i>Prevotella levii</i> (1)	<0.4	>200	100	200	>200
<i>Prevotella loescheii</i> (1)	<0.4	>200	>200	200	>200
<i>Porphyromonas asaccharolytica</i> (1)	<0.4	50	100	50	200
<i>Porphyromonas gingivalis</i> (1)	<0.4	50	100	100	200
Reference strains:					
<i>Bacteroides fragilis</i> ATCC 25285	<0.4	200	>200	>200	>200
<i>Fingoldia magna</i> ATCC 29328	<0.4	200	100	50	200
<i>Peptostreptococcus anaerobius</i> ATCC 27331	<0.4	100	100	100	200
<i>Bifidobacterium breve</i> ATCC 15700	50	200	200	≥ 200	200
<i>Parabacteroides distasonis</i> ATCC 8503	<0.4	>200	>200	>200	>200
<i>Fusobacterium nucleatum</i> ATCC 25586	<0.4	>200	>200	>200	>200
	2e	2f	2g	2h	2i
Gram-positive cocci:					
<i>Fingoldia magna</i> (3)	≥ 200	≥ 200	≥ 200 , 100, 25	200, 100(2)	50, 12.5, <6.2
<i>Parvimonas micra</i> (2)	100, 25	50, 25	50, 25	25, 12.5	25, 12.5
<i>Peptostreptococcus anaerobius</i> (1)	100	100	50	100	25
Gram-positive rods:					
<i>Bifidobacterium breve</i> (2)	200, 100	100	100, 50	100, 50	12.5, <6.2
<i>Propionibacterium acnes</i> (1)	100	100	≥ 200	100	100
<i>Propionibacterium granulosum</i> (2)	200, 100	100	≥ 200	100	≥ 200
Gram-negative rods:					
<i>Bacteroides fragilis</i> (1)	>200	>200	50	>200	>200
<i>Bacteroides uniformis</i> (1)	>200	100	25	>200	>200
<i>Bacteroides ureolyticus</i> (1)	>200	>200	≥ 200	>200	>200
<i>Bacteroides vulgatus</i> (1)	100	200	50	100	100
<i>Prevotella levii</i> (1)	200	100	50	200	>200
<i>Prevotella loescheii</i> (1)	>200	≥ 200	>200	200	200
<i>Porphyromonas asaccharolytica</i> (1)	200	≥ 200	50	>200	200
<i>Porphyromonas gingivalis</i> (1)	>200	>200	>200	>200	>200
Reference strains:					
<i>Bacteroides fragilis</i> ATCC 25285	>200	>200	100	>200	200
<i>Fingoldia magna</i> ATCC 29328	>200	100	100	200	200
<i>Peptostreptococcus anaerobius</i> ATCC 27331	200	100	100	100	100
<i>Bifidobacterium breve</i> ATCC 15700	200	≥ 200	100	100	200
<i>Parabacteroides distasonis</i> ATCC 8503	>200	>200	>200	>200	>200
<i>Fusobacterium nucleatum</i> ATCC 25586	>200	>200	>200	>200	>200

greater at the vicinity of the isoxazolone N1 nitrogen atom than at the pyridine N7 atom. These results indicate that the orbital-controlled reactions of **1** take place

exclusively because no N7-alkylation or acylation products resulting from electrostatically-controlled reaction were observed.

Table 2 *In vitro* antibacterial activity of compounds **1**, **2g**, **2f**, **2i** against aerobic bacterial strains.

Bacteria (number of strains)	Minimum inhibitory concentration (MIC, $\mu\text{g mL}^{-1}$)				
	Amikacin	1	2g	2f	2i
Gram-positive cocci:					
<i>Staphylococcus aureus</i> (3)	≤ 6.2	≥ 200	100	100	≥ 200
<i>Staphylococcus aureus</i> (MRSA) (3)	≥ 200	≥ 200	100	$\geq 200(2), 100$	≥ 200
<i>Staphylococcus epidermidis</i> (2)	≤ 6.2	$> 200, 50$	100, 50	100, 50	$> 200, 25$
<i>Streptococcus pyogenes</i> (1)	50	100	100	100	> 200
<i>Streptococcus anginosus</i> (2)	100, 50	100, 50	–	–	50
<i>Enterococcus faecalis</i> (2)	50, 25	50	100	100	200, 50
Gram-positive rods:					
<i>Corynebacterium ulcerans</i> (2)	50, 25	100	100	100	$\geq 200, 100$
<i>Corynebacterium xerosis</i> (1)	50	100	25	50	100
Gram-negative rods:					
<i>Escherichia coli</i> (2)	12.5, ≤ 6.2	100	≥ 200	≥ 200	≥ 200
<i>Acinetobacter baumannii</i> (1)	< 6.2	> 200	> 200	100	> 200
<i>Citrobacter freundii</i> (2)	≤ 6.2	200	$> 200, 100$	200, 100	≥ 200
<i>Klebsiella pneumoniae</i> (2)	≤ 6.2	≥ 200	100	$\geq 200, 100$	≥ 200
<i>Serratia marcescens</i> (1)	< 6.2	50	100	100	> 200
<i>Pseudomonas aeruginosa</i> (2)	12.5	≥ 200	$> 200, 100$	$> 200, 100$	≥ 200
<i>Pseudomonas stutzeri</i> (2)	≤ 6.2	≥ 200	100	100	≥ 200
Reference strains:					
<i>Staphylococcus aureus</i> ATCC 25923	< 6.2	> 200	> 200	> 200	> 200
<i>Enterococcus faecalis</i> ATCC 29212	25	100	> 200	> 200	> 200
<i>Corynebacterium xerosis</i> ATCC 373	25	200	100	100	100
<i>Klebsiella pneumoniae</i> ATCC 13883	< 6.2	> 200	100	> 200	> 200
<i>Acinetobacter baumannii</i> ATCC 19606	< 6.2	> 200	> 200	≥ 200	> 200
<i>Escherichia coli</i> ATCC 25922	< 6.2	200	> 200	> 200	> 200

Antibacterial activity

The results of *in vitro* antibacterial activity of compounds **1**, **2a,b**, **2d–i** against anaerobic bacterial strains and compounds **1**, **2g**, **2f**, **2i** against aerobic bacterial strains are presented in Tables 1 and 2, respectively. The tested compounds show moderate potencies against anaerobic bacteria as they inhibit growth of 15–47% strains at concentrations in the range ≤ 6.2 –100 $\mu\text{g/mL}$. The most potent methyl propanoate **2g** displays broad activity against 47% of bacterial strains, with minimal inhibitory concentration (MIC) values in the range 25–100 $\mu\text{g/mL}$. The unsubstituted 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) inhibits growth of 15 strains (44%) at concentrations in the range 25–100 $\mu\text{g/mL}$, whereas the remaining seven congeners exhibit relatively weaker biological activities: the methyl derivative **2a** is active against 13 bacterial strains (38%, MIC 50–100 $\mu\text{g/mL}$), **2b**, **2f** and **2h** show potent activity against 12 strains (35%, MIC ≤ 6.2 –100 $\mu\text{g/mL}$) and compounds **2i** and **2e** inhibit growth of 11 (32%, MIC ≤ 6.2 –50 $\mu\text{g/mL}$) and seven strains (21%, 25–100 $\mu\text{g/mL}$), respectively. The benzyl (**2d**) derivative proved to be the least active, whereas the butyl congener (**2c**) does not

exert any antibacterial effect, probably due to its poor solubility. All tested compounds are more active against Gram-positive cocci (12–32% susceptible strains) than Gram-positive rods (3–15% susceptible strains). The most susceptible genera among Gram-positive cocci and Gram-positive rods are *Parvimonas micra* and *Bifidobacterium breve*, respectively. Among anaerobes, the following strains exhibit high resistance towards all tested compounds (MIC ≥ 200 $\mu\text{g/mL}$): *Parabacteroides distasonis* (1), *Prevotella bivia* (1), *Prevotella buccalis* (1), *Prevotella intermedia* (2), *Fusobacterium nucleatum* (2), *Fusobacterium necrophorum* (2), *Parabacteroides distasonis*, ATCC 8503 and *Fusobacterium nucleatum* ATCC 25586.

Aerobic bacterial strains exhibit susceptibility to only four tested compounds at the concentrations in the range of 25–100 $\mu\text{g/mL}$. The most potent derivative **2g** exhibits activity against 22 (65%) bacterial strains, with MIC values in the range of 50–100 $\mu\text{g/mL}$. The unsubstituted and hydroxyethyl congeners **1** and **2f** inhibit growth of 13 (38%) and 20 strains (59%), respectively, at concentrations in the range of 25–100 $\mu\text{g/mL}$.

Gram-positive aerobic cocci and rods proved to be more susceptible than Gram-negative rods to the four tested

compounds. Among Gram-positive bacteria the *Staphylococcus epidermidis*, *Enterococcus faecalis* and *Corynebacterium xerosis* are the most susceptible genera (MIC in the range 25–100 µg/mL). By contrast, *Staphylococcus aureus* and methicillin resistant *Staphylococcus aureus* (MRSA) are susceptible to compounds **2g** and **2f**. Generally, the Gram-negative rods are most resistant to the genera tested as growths of only a few strains of *Citrobacter freundii*, *Klebsiella pneumoniae*, *Serratia marcescens* and *Pseudomonas stutzeri* are inhibited at concentrations of 50–100 µg/mL. Among all the tested compounds, only **1**, **2f**, **2g** and **2i** are active against both aerobic and anaerobic bacterial strains. The most active compound in this category is the methyl propanoate **2g**, which inhibits 56% of the bacterial strains tested.

Compounds **2a**, **2h**, **2d** and **2i** were also evaluated for their cytotoxic activity [35, 36] against five human cancer cell lines: uterine cervical adenocarcinoma SISO, lung cancer LCLC and A-427, pancreas adenocarcinoma DAN-G and neural cell line RT-4. However, the tested compounds did not exhibit cytotoxic activity at concentrations of up to 20 µM.

Experimental

All chemicals were purchased from commercial sources and used without further purification. Silica gel chromatography was performed with use of silica gel 60 PF₂₅₄ containing gypsum for preparative layer chromatography and chromatotron. ¹H and ¹³C NMR data were obtained using 200 MHz or 50 MHz spectrometers, respectively. ¹H NMR data were internally referenced to TMS (0.0 ppm) or DMSO-*d*₆ (2.5 ppm); ¹³C NMR spectra were referenced to CDCl₃ (77.23 ppm) or DMSO-*d*₆ (39.50 ppm). The IR spectra were recorded using KBr pellets.

4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (1)

N-Hydroxy-3-(hydroxyamino)-3-iminopropanamide [14] (1.3 g, 9.8 mmol), acetylacetone (1 mL, 9.8 mmol) and piperidine (1 mL, 9.8 mmol) were heated under reflux in water (30 mL) for 15 min. After cooling to room temperature the reaction mixture was acidified with 5% HCl and the resultant yellow precipitate was filtered off and washed with water (2 × 3 mL); yield 1.2 g (75%); mp 204–207°C (lit. mp 204°C [13]); IR: 3372, 2725, 1694, 1670, 1640, 1619, 1531, 1350, 1289, 1051, 1030, 980, 938, 823, 784 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.38 (s, 3H, CH₃), 2.45 (s, 3H, CH₃), 6.38 (s, 1H, CH), 13.00 (bs, 1H, NH); ¹³C NMR (DMSO-*d*₆): δ 16.7, 21.3, 100.8, 112.7, 155.9, 158.1, 159.9, 169.0; MS (ESI): *m/z* 163 [M+1].

General procedure for compounds 2a–g

4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**), alkyl halide and triethylamine were allowed to react at room temperature as indicated below. After 12 h the mixture was concentrated under reduced

pressure and the residue was treated with water (5 mL) and dichloromethane (10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The crude compound was purified on a chromatotron eluting with the solvent indicated below.

1,4,6-Trimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2a) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.3 g, 1.83 mmol), methyl iodide (0.34 mL, 5.49 mmol) and triethylamine (0.51 mL, 3.66 mmol) were added to the mixture of chloroform (3 mL) and DMF (1 mL); eluent: petroleum ether-dichloromethane, 1:1, v/v; yield 0.16 g (49%); mp 72–75°C; IR: 2921, 1749, 1618, 1598, 1437, 11371, 1284, 1180, 1110, 1035, 1009, 869, 800 cm⁻¹; ¹H NMR (CDCl₃): δ 2.57 (s, 3H, CH₃), 2.60 (s, 3H, CH₃), 3.47 (s, 3H, CH₃), 6.81 (s, 1H, CH); ¹³C NMR (CDCl₃): δ 17.5, 25.4, 40.1, 102.4, 121.2, 151.1, 166.6, 166.8, 168.6; MS (ESI): *m/z* 179 [M+1]⁺. Anal. Calcd for C₉H₁₀N₂O₂: C, 60.66; H, 5.66; N, 15.72. Found: C, 60.51; H, 5.78; N, 15.56.

1-Ethyl-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2b) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.3 g, 1.83 mmol), ethyl iodide (0.29 mL, 3.66 mmol) and triethylamine (0.51 mL, 3.66 mmol) were added to the mixture of chloroform (3 mL) and DMF (1 mL); eluent: petroleum ether-dichloromethane, 1:1, v/v; yield 0.267 g (76%); mp 55–58°C; IR: 2982, 1758, 1613, 1371, 1278, 1172, 1082, 1018, 931, 845, 806, 737, 702, 613, 548, 501 cm⁻¹; ¹H NMR (CDCl₃): δ 1.26 (t, *J* = 7.0 Hz, 3H, CH₃), 2.56 (s, 3H, CH₃), 2.59 (s, 3H, CH₃), 3.87 (q, *J* = 7.0 Hz, 2H, CH₂), 6.79 (s, 1H, CH); ¹³C NMR (CDCl₃): δ 11.7, 17.5, 25.5, 48.3, 102.8, 121.0, 150.9, 166.8 (two signals), 167.6; MS (ESI): *m/z* 193 [M+1]⁺. Anal. Calcd for C₁₀H₁₂N₂O₂: C, 62.49; H, 6.29; N, 14.57. Found: C, 62.57; H, 6.33; N, 14.34.

1-Butyl-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2c) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.3 g, 1.83 mmol), butyl iodide (0.41 mL, 3.66 mmol) and triethylamine (0.51 mL, 3.66 mmol) were added to the mixture of chloroform (3 mL) and DMF (1 mL); eluent: petroleum ether-dichloromethane, 1:1, v/v; yield 0.25 g (62%); mp 22–25°C; IR: 2961, 2934, 2873, 1762, 1613, 1593, 1443, 1376, 1283, 1173, 1024, 802, 702, 612 cm⁻¹; ¹H NMR (CDCl₃): δ 0.95 (t, *J* = 7.0 Hz, 3H, CH₃), 1.37–1.48 (m, 2H, CH₂), 1.66–1.77 (m, 2H, CH₂), 2.56 (s, 3H, CH₃), 2.60 (s, 3H, CH₃), 3.79 (q, *J* = 7.0 Hz, 2H, CH₂), 6.78 (s, 1H, CH); ¹³C NMR (CDCl₃): δ 14.2, 17.5, 20.4, 25.5, 29.0, 53.1, 102.3, 120.9, 151.0, 166.8 (two signals), 167.6; MS (ESI): *m/z* 221 [M+1]⁺. Anal. Calcd for C₁₂H₁₆N₂O₂: C, 65.43; H, 7.32; N, 12.72. Found: C, 65.64; H, 7.19; N, 12.48.

1-Benzyl-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2d) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.2 g, 1.22 mmol), benzyl bromide (0.16 mL, 1.34 mmol) and triethylamine (0.17 mL, 1.34 mmol) were added to the mixture of chloroform (3 mL) and DMF (1 mL); eluent: dichloromethane; yield 0.26 g (84%); mp 100–103°C; IR: 3030, 2950, 1761, 1612, 1592, 1434, 1376, 1174, 1031, 798, 760, 738, 703, 637 cm⁻¹; ¹H NMR (CDCl₃): δ 2.56 (s, 3H, CH₃), 2.61 (s, 3H, CH₃), 4.99 (s, 2H, CH₂), 6.80 (s, 1H, CH), 7.27–7.39 (m, 5H, CH); ¹³C NMR (CDCl₃): δ 17.5, 25.5, 57.0, 103.0, 121.2, 128.7, 129.0, 129.7, 134.2, 151.0, 166.5, 166.8, 167.4; MS (ESI): *m/z* 255 [M+1]⁺. Anal. Calcd for C₁₅H₁₄N₂O₂: C, 70.85; H, 5.55; N, 11.02. Found: C, 70.73; H, 5.76; N, 10.81.

1-(3,5-Dimethoxybenzyl)-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2e) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.2 g, 1.22 mmol), 3,5-dimethoxybenzyl bromide (0.28 mL, 1.34 mmol) and triethylamine (0.17 mL, 1.34 mmol) were added to DMF (3 mL); eluent: dichloromethane; yield 0.32 g (83%); mp 108–113°C; IR: 2947, 2843, 1761, 1601, 1474, 1452, 1438, 1393, 1375, 1354, 1296, 1276, 1206,

1170, 1161, 1068, 1054, 1032, 983, 962, 912, 837, 806, 743, 720 cm^{-1} ; ^1H NMR (CDCl_3): δ 2.58 (s, 3H, CH_3), 2.60 (s, 3H, CH_3), 3.75 (s, 6H, CH_3), 4.92 (s, 2H, CH_2), 6.38 (s, 1H, CH), 6.52 (s, 2H, CH), 6.80 (s, 1H, CH); ^{13}C NMR (CDCl_3): δ 17.3, 25.2, 55.6, 56.8, 100.6, 102.8, 107.1, 121.0, 136.2, 150.9, 161.0, 166.2, 166.4, 167.0; MS (ESI): m/z 315 $[\text{M}+1]^+$. Anal. Calcd for $\text{C}_{17}\text{H}_{18}\text{N}_2\text{O}_4$: C, 64.96; H, 5.77; N, 8.91. Found: C, 64.75; H, 6.16; N, 8.62.

1-(2-Hydroxyethyl)-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2f) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.1 g, 0.61 mmol), 2-bromoethanol (0.38 mL, 3.04 mmol) and triethylamine (0.17 mL, 1.22 mmol) were added to DMF (3 mL); eluent: ethyl acetate-dichloromethane, 5:95, v/v; yield 0.08 g (63%); mp 84–85°C; IR: 3489, 3044, 2923, 1743, 1613, 1590, 1445, 1407, 1373, 1359, 1277, 1180, 1073, 1028, 881, 801, 703, 614 cm^{-1} ; ^1H NMR (CDCl_3): δ 2.56 (s, 3H, CH_3), 2.60 (s, 3H, CH_3), 3.87–3.92 (m, 2H, CH_2), 4.01–4.06 (m, 2H, CH_2), 6.82 (s, 1H, CH); ^{13}C NMR (CDCl_3): δ 17.6, 25.4, 56.4, 59.9, 102.4, 121.3, 151.7, 166.1, 166.6, 167.4; MS (ESI): m/z 209 $[\text{M}+1]^+$. Anal. Calcd for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}_3$: C, 57.68; H, 5.81; N, 13.45. Found: C, 57.32; H, 6.08; N, 13.23.

Methyl 3-(4,6-dimethyl-3-oxoisoxazolo[3,4-*b*]pyridin-1(3*H*)-yl)propanoate (2g) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.1 g, 0.61 mmol), methyl 3-bromopropionate (0.20 mL, 1.83 mmol) and triethylamine (0.17 mL, 1.22 mmol) were added to DMF (3 mL); eluent: ethyl acetate-dichloromethane, 1:99, v/v; yield 0.12 g (79%); mp 33–34°C; IR: 3010, 2959, 2926, 1760, 1727, 1619, 1591, 1445, 1372, 1269, 1248, 1198, 1173, 1032, 1017, 803 cm^{-1} ; ^1H NMR (CDCl_3): δ 2.56 (s, 3H, CH_3), 2.59 (s, 3H, CH_3), 2.77 (t, 2H, CH_2 , $J = 7.0$ Hz), 3.70 (s, 3H, CH_3), 4.10 (t, 2H, CH_2 , $J = 7.0$ Hz), 6.82 (s, 1H, CH); ^{13}C NMR (CDCl_3): δ 17.5, 25.5, 31.8, 49.1, 52.4, 102.7, 121.5, 151.1, 166.4, 167.0, 167.6, 171.7; MS (ESI): m/z 251 $[\text{M}+1]^+$. Anal. Calcd for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_4$: C, 57.59; H, 5.64; N, 11.19. Found: C, 57.30; H, 5.96; N, 11.01.

4,6-Dimethyl-1-(methylsulfonyl)isoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2h) 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.2 g, 1.22 mmol), NaOH (0.6 g, 15 mmol) and methanesulfonyl chloride (0.45 mL, 5.8 mmol) were added to water (12 mL), and the resulting mixture was stirred at room temperature for 0.5 h and then extracted with dichloromethane (2×10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give crude compound **2i**, which was further purified by use of chromatotron; eluent: dichloromethane; yield 0.17 g (58%); mp 130–136°C; IR: 3020, 3010, 2927, 1783, 1762, 1618, 1585, 1387, 1364, 1334, 1321, 1284, 1243, 1181, 1172, 1033, 966, 815, 797, 759, 737, 697, 660, 607, 552, 514 cm^{-1} ; ^1H NMR (CDCl_3): δ 2.67 (s, 3H, CH_3), 2.69 (s, 3H, CH_3), 3.36 (s, 3H, CH_3), 7.13 (s, 1H, CH); ^{13}C NMR (CDCl_3): δ 17.3, 25.5, 39.2, 105.1, 124.8, 151.7, 162.2, 164.4, 167.9; MS (ESI): m/z 243 $[\text{M}+1]^+$. Anal. Calcd for $\text{C}_9\text{H}_{10}\text{N}_2\text{O}_4\text{S}$: C, 44.62; H, 4.16; N, 11.56. Found: C, 44.37; H, 4.35; N, 11.47.

1-Acetyl-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (2i) To the solution of 4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one (**1**) (0.2 g, 1.22 mmol) in pyridine (0.6 mL) acetic anhydride (0.4 mL, 4.24 mmol) was added and the resulting orange mixture was stirred at room temperature to discolor. The precipitated white solid was filtered and dried under reduced pressure; yield 0.17 g (68%); mp 188–194°C (lit. mp 195°C [13, 15]); IR: 3048, 2953, 1785, 1709, 1615, 1591, 1438, 1395, 1376, 1298, 1264, 1176, 1164, 1070, 1034, 887, 852, 791, 618, 604 cm^{-1} ; ^1H NMR (CDCl_3): δ 2.62 (s, 3H, CH_3), 2.63 (s, 3H, CH_3), 2.69 (s, 3H, CH_3), 6.98 (s, 1H, CH); ^{13}C NMR (CDCl_3): δ 17.7, 24.1, 25.8, 102.2, 122.8, 151.7, 157.2, 162.0, 163.2, 167.8; MS (ESI): m/z 207 $[\text{M}+1]^+$.

Antibacterial activity tests

The investigations included 28 strains of anaerobic bacteria and 28 strains of aerobic bacteria isolated from the oral cavity, respiratory system and intestinal tract as well as 12 reference strains. The anaerobes belonged to the following genera: *Finegoldia magna* (3), *Parvimonas micra* (2), *Peptostreptococcus anaerobius* (1), *Bifidobacterium breve* (2), *Propionibacterium acnes* (1), *Propionibacterium granulosum* (2), *Bacteroides fragilis* (1), *Bacteroides uniformis* (1), *Bacteroides ureolyticus* (1), *Bacteroides vulgatus* (1), *Parabacteroides distasonis* (1), *Prevotella bivia* (1), *Prevotella buccalis* (1), *Prevotella intermedia* (2), *Prevotella levii* (1), *Prevotella loescheii* (1), *Porphyromonas asaccharolytica* (1), *Porphyromonas gingivalis* (1), *Fusobacterium nucleatum* (2), *Fusobacterium necrophorum* (2) and following reference strains: *Bacteroides fragilis* ATCC 25285, *Parabacteroides distasonis* ATCC 8503, *Fusobacterium nucleatum* ATCC 25586, *Finegoldia magna* ATCC 29328, *Peptostreptococcus anaerobius* ATCC 27331, *Bifidobacterium breve* ATCC 15700. There were also the following aerobes used: *Staphylococcus aureus* (3), *Staphylococcus aureus* methicillin resistant (MRSA) (3), *Staphylococcus epidermidis* (2), *Streptococcus pyogenes* (1), *Streptococcus anginosus* (2), *Enterococcus faecalis* (2), *Corynebacterium ulcerans* (2), *Corynebacterium xerosis* (1), *Escherichia coli* (2), *Acinetobacter baumannii* (1), *Citrobacter freundii* (2), *Klebsiella pneumoniae* (2), *Serratia marcescens* (1), *Pseudomonas aeruginosa* (2), *Pseudomonas stutzeri* (2) and six reference strains: *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Corynebacterium xerosis* ATCC 373, *Klebsiella pneumoniae* ATCC 13883, *Acinetobacter baumannii* ATCC 19606, *Escherichia coli* ATCC 25922. The susceptibility of the anaerobic bacteria was determined by means of the plate dilution technique in Brucella agar, supplemented with 5% defibrinated sheep's blood [37, 38]. For aerobic bacteria experiments, the agar dilution technique with Mueller-Hinton agar was used [39, 40]. The derivatives were dissolved in 1 mL of DMSO immediately before the experiment. Sterile distilled water was used for further dilutions. The following concentrations of derivatives were used: 200, 100, 50, 25, 12.5 and 6.2 $\mu\text{g/mL}$. The inoculum containing 10^5 CFU/spot was applied to the appropriate agar plates with Steers replicator. For aerobes, the inoculated agar plates and agar plates without derivatives were incubated for 24 h at 37°C. For anaerobes, agar plates were incubated in anaerobic jars for 48 h at 37°C in 10% CO_2 , 10% H_2 and 80% N_2 with palladium catalyst and indicator for anaerobiosis. The MIC was defined as the lowest concentration of the derivative that inhibited growth of the tested bacteria [39–41].

Acknowledgments: This work was supported by Polish Ministry of Science and Higher Education and National Science Centre, research grant IP2012 055472. We thank Professor Patrick J. Bednarski (University of Greifswald, Germany) for cytotoxicity assessments.

References

- [1] Chande, M. S.; Verma, R. S.; Barve, P. A.; Khanwelkar, R. R.; Vaidya, R. B.; Ajaikumar, K. B. Facile synthesis of active antitubercular, cytotoxic and antibacterial agents: a Michael addition approach. *Eur. J. Med. Chem.* **2005**, *40*, 1143–1148.

- [2] Yu, M.; Wang, J.; Tang, K.; Shi, X.; Wang, S.; Zhu, W.-M.; Zhang, X.-H. Purification and characterization of antibacterial compounds of *Pseudoalteromonas flavipulchra* JG1. *Microbiology (Reading, UK)* **2012**, *158*, 835–842.
- [3] Padmavathi, V.; Subbaiah, D. R. C. V.; Mahesh, K.; Lakshmi, T. R. Synthesis and bioassay of amino-pyrazolone, amino-isoxazolone and amino-pyrimidinone derivatives. *Chem. Pharm. Bull.* **2007**, *55*, 1704–1709.
- [4] Wierenga, W.; Evans, B. R.; Zurenko, G. E. Benzisoxazolones: antimicrobial and antileukemic activity. *J. Med. Chem.* **1984**, *27*, 1212–1215.
- [5] Brauholtz, J. T.; Freeman, P. F. H. Fungicidal isoxazolones. *GB1074803*, **1967**.
- [6] Das, N. P.; Mishra, P. K.; Sahu, S. Fungicidal activity of some substituted 5-isoxazolones. *Acta Cienc. Indica Chem.* **2011**, *37*, 239–243.
- [7] Ishioka, T.; Tanatani, A.; Nagasawa, K.; Hashimoto, Y. Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2655–2658.
- [8] Laughlin, S. K.; Clark, M. P.; Djung, J. F.; Golebiowski, A.; Brugel, T. A.; Sabat, M.; Bookland, R. G.; Laufersweiler, M. J.; VanRens, J. C.; Townes, J. A.; et al. The development of new isoxazalone based inhibitors of tumor necrosis factor- α production. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2399–2403.
- [9] Laufer, S. A.; Margutti, S. Isoxazolone based inhibitors of p38 MAP kinases. *J. Med. Chem.* **2008**, *51*, 2580–2584.
- [10] Sączewski, J.; Hinc, K.; Obuchowski, M.; Gdaniec, M. The tandem Mannich-electrophilic amination reaction: a versatile platform for fluorescent probing and labeling. *Chem. Eur. J.* **2013**, *19*, 11531–11535.
- [11] Sączewski, J.; Korcz, M. Synthesis and reactivity of heterocyclic hydroxylamine-*O*-sulfonates. *Heterocycl. Commun.* **2014**, *20*, 133–148.
- [12] Sączewski, J.; Gdaniec, M. Synthesis and molecular structure of (Z)-1*H*-purin-6-ylideneaminoxy-sulfonic acid: a possible secondary metabolite of adenine. *Heterocycl. Commun.* **2012**, *18*, 109–112.
- [13] Khan, M. A.; Rafala, F. K. Synthesis of isoxazolo[3,4-*b*]pyridin-3(1*H*)-one and isoxazolo[5,4-*b*]pyridin-3(2*H*)-one. *J. Chem. Soc. Perkin Trans. I* **1975**, 693–694.
- [14] Bauer, L.; Nambury, N. N. V. Synthesis of aminoisoxazolones from α -cyano esters and hydroxylamine. *J. Org. Chem.* **1961**, *26*, 4917–4922.
- [15] Hamid, M. A.; Hempel, A. 1-Acetyl-4,6-dimethylisoxazolo[3,4-*b*]pyridin-3(1*H*)-one. *Acta Crystallogr. Sect. B* **1979**, *B35*, 470–471.
- [16] Alkorta, I.; Sánchez-Sanz, G.; Trujillo, C.; Elguero, J.; Claramunt, R. M. A theoretical study of the parent *NH*-benzazoles (benzimidazoles, indazoles and benzotriazoles): geometries, energies, acidity and basicity, NMR properties and molecular electrostatic potentials. *Arkivoc* **2012**, *ii*, 85–106.
- [17] Kolodobsii, G. I.; Oastrovskii, V. A. Acid-base properties of five-membered nitrogen-containing heterocycles. *Chem. Heterocycl. Compounds* **1988**, *24*, 469–480.
- [18] *Spartan '08 for Windows*, Irvine, CA: Wavefunction, Inc.; www.wavefun.com.
- [19] Marenich, A. V.; Olson, R. M.; Kelly, C. P.; Cramer, C. J.; Truhlar, D. G. Self-consistent reaction field model for aqueous and nonaqueous solutions based on accurate polarized partial charges. *J. Chem. Theory Comput.* **2007**, *3*, 2011–2033.
- [20] Gupta, R.; Chaudhary, R. P. Synthesis, antimicrobial and DFT studies of novel fused thiazolopyrimidine derivatives. *Heterocycl. Commun.* **2013**, *19*, 207–214.
- [21] Guemues, S.; Tuerker, L. Substituent effect on the aromaticity of 1,3-azole systems. *Heterocycl. Commun.* **2012**, *18*, 11–16.
- [22] Antonov, L. Tautomerism: Methods and Theories; Wiley-VCH Verlag GmbH & Co. KGaA: Hoboken, NJ, 2014.
- [23] Katritzky, A.; Karelson, H.; Harris, P. Prototropic tautomerism of heteroaromatic compounds. *Heterocycles* **1991**, *32*, 329–369.
- [24] Kang, Y. K.; Sook Park, H. Ab initio conformational study of *N*-acetyl-L-proline-*N'*,*N'*-dimethylamide: a model for polypyrrolone. *Biophys. Chem.* **2005**, *113*, 93–101.
- [25] Shabanian, M.; Hajibeygi, M.; Moghanian, H.; Mohamadi, A. Theoretical investigation on tautomerism and NBO analysis of 3-hydroxy-1,2,5-thiadiazole derivatives: solvent and substituent effects. *Heterocycl. Commun.* **2012**, *18*, 161–164.
- [26] Hempel, A.; Hamid, M. A. 4,6-Dimethylisoxazolo[3,4-*b*]pyridin-3(7*H*)-one monohydrate. *Acta Crystallogr. Sect. B* **1979**, *B35*, 471–473.
- [27] Katritzky, A. R.; Ramsden, Ch.; Joule, J.; Zhdankin, V. Handbook of Heterocyclic Chemistry; Elsevier: Philadelphia, PA, **2010**.
- [28] Karelson, M. M.; Katritzky, A. R.; Szafran, M.; Zerner, M. C. A theoretical treatment of solvent effects on the tautomeric equilibria of five-membered rings with two heteroatoms. *J. Chem. Soc. Perkin Trans. 2* **1990**, *1*, 195–201.
- [29] Yi, P. G.; Liang, Y. H.; Tang, Z. Q. Theoretical study of intermolecular proton transfer reaction in isolated 5-hydroxyisoxazole-water complexes. *Chem. Phys.* **2006**, *322*, 387–391.
- [30] Beak, P.; Lee, J.; McKinnie, B. G. Methylation of protomeric ambident nucleophiles with methyl fluorosulfonate: a regio-specific reaction. *J. Org. Chem.* **1978**, *43*, 1367–1372.
- [31] Abarghaz, M.; Kerbal, A.; Bourguignon, J.-J. Regioselective alkylation of the exocyclic nitrogen of heterocyclic amidines via the Mitsunobu reaction. *Tetrahedron Lett.* **1995**, *36*, 6463–6466.
- [32] Novak, L.; Hornyanszky, G.; Kiraly, I.; Rohaly, J.; Kolonits, P.; Szantay, C. Preparation of new imidacloprid analogues. *Heterocycles* **2001**, *55*, 45–48.
- [33] Sączewski, J.; Gdaniec, M. Regioselective reaction of 2-hydroxyyliminoimidazolidine-*O*-sulfonate with benzyl bromides. *Pol. J. Chem.* **2008**, *82*, 2107–2113.
- [34] Sączewski, J.; Hudson, A.; Laird, S.; Rybczyńska, A.; Boblewski, K.; Lehmann, A.; Ma, D.; Maze, M.; Watts, H.; Gdaniec, M. *N*-(Imidazolidin-2-ylidene)-1-arylmethanamine oxides: synthesis, structure and pharmacological evaluation. *Arch. Pharm.* **2012**, *345*, 33–42.
- [35] Bracht, K.; Boubakari, Grünert, R.; Bednarski, P. J. Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. *Anticancer Drugs* **2006**, *17*, 41–51.
- [36] Ivanova, Y. B.; Momekov, G. T.; Petrov, O. I. New heterocyclic chalcones. Part 6. Synthesis and cytotoxic activities of 5- or 6-(3-aryl-2-propenoyl)-2(3*H*)-benzoxazolones. *Heterocycl. Commun.* **2013**, *19*, 23–28.
- [37] Balows, A.; Hausler, H. J.; Herrmann, K. L.; Isenberg, H. D.; Shadomy, H. J. Manual of Clinical Microbiology; 5th Edition. American Society for Microbiology: Washington, DC, 1991.

- [38] Baron, E. J.; Tenenbaum, S. M. Bailey and Scott's Diagnostic Microbiology; 8th Edition. C.V. Mosby Co.: St. Louis, MO, 1990.
- [39] Forbes, B. A.; Sahn, D. F.; Weissfeld, A. S. Bailey and Scott's Diagnostics Microbiology; 12th Edition. Mosby Elsevier, St. Louis, MO, 2007.
- [40] Clinical and Laboratory Standards Institute/NCCLS. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria that Grow Aerobically; Approved standards 7th Edition. CLSI document M7-A7. Clinical and Laboratory Standards Institute: Wayne, PA, 2006.
- [41] Clinical and Laboratory Standards Institute/NCCLS. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved standards 7th Edition. CLSI document M11-A7. Clinical and Laboratory Standards Institute: Wayne, PA, 2007.